Cancer Immunology
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributio...
保存先:
| フォーマット: | Online |
|---|---|
| 言語: | 英語 |
| 出版事項: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| 主題: | |
| オンライン･アクセス: | ONIX_20220111_9783036525730_940 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
| _version_ | 1869522035404701696 |
|---|---|
| collection | Directory of Open Access Books |
| description | The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue. |
| format | Online |
| id | doab-20.500.12854ir-77108 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-771082024-03-30T23:22:57Z Cancer Immunology Subramanian, Subree Zhao, Xianda NKG2D CAR T IL-7 prostate cancer cell therapy CD19-CAR-T B cell aplasia KIR PD-1 inhibitory CAR tumor-infiltrating lymphocytes tumor microenvironment immunotherapy NK cells cancer stem cells (CSCs) antibody-dependent cellular cytotoxicity (ADCC) differentiation cytotoxicity IFN-γ osteoclasts MICA/B mAb DNA methylation RNA methylation S-adenosylmethionine (SAM) cancer innate immunity adaptive immunity T cells m6A PD-L1 resistance immune checkpoints cancer vaccine combination immunotherapy TCR diversity organ transplantation carcinoma epidemiologic studies immunosuppression CTLA-4 Treg cells immune checkpoint inhibitors CD28 antigen-presenting cells IL15 colon cancer melanoma uveal BAP1 anti-PD-1 anti-CTLA-4 TIL classical and endemic Kaposi Sarcoma systemic treatment multi-state modelling treatment free interval chemotherapy interferon triple negative breast cancer immunomodulation bispecific antibody sortase A chemo-enzymatic approach anti-CD20 antibody Fab BiFab colorectal cancer dendritic cells Atypical Chemokine Receptor 4 (ACKR4) T-cell priming immune checkpoint blockade primary liver cancer kynurenine pathway immune evasion indoleamine 2,3 dioxygenase 1 tryptophan 2,3 dioxygenase 2 IDO inhibitor antigen presenting cells n/a thema EDItEUR::M Medicine and Nursing The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue. 2022-01-11T13:52:29Z 2022-01-11T13:52:29Z 2021 book ONIX_20220111_9783036525730_940 9783036525730 9783036525723 https://directory.doabooks.org/handle/20.500.12854/77108 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4727 https://mdpi.com/books/pdfview/book/4727 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2572-3 10.3390/books978-3-0365-2572-3 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036525730 9783036525723 316 Basel, Switzerland open access |
| spellingShingle | NKG2D CAR T IL-7 prostate cancer cell therapy CD19-CAR-T B cell aplasia KIR PD-1 inhibitory CAR tumor-infiltrating lymphocytes tumor microenvironment immunotherapy NK cells cancer stem cells (CSCs) antibody-dependent cellular cytotoxicity (ADCC) differentiation cytotoxicity IFN-γ osteoclasts MICA/B mAb DNA methylation RNA methylation S-adenosylmethionine (SAM) cancer innate immunity adaptive immunity T cells m6A PD-L1 resistance immune checkpoints cancer vaccine combination immunotherapy TCR diversity organ transplantation carcinoma epidemiologic studies immunosuppression CTLA-4 Treg cells immune checkpoint inhibitors CD28 antigen-presenting cells IL15 colon cancer melanoma uveal BAP1 anti-PD-1 anti-CTLA-4 TIL classical and endemic Kaposi Sarcoma systemic treatment multi-state modelling treatment free interval chemotherapy interferon triple negative breast cancer immunomodulation bispecific antibody sortase A chemo-enzymatic approach anti-CD20 antibody Fab BiFab colorectal cancer dendritic cells Atypical Chemokine Receptor 4 (ACKR4) T-cell priming immune checkpoint blockade primary liver cancer kynurenine pathway immune evasion indoleamine 2,3 dioxygenase 1 tryptophan 2,3 dioxygenase 2 IDO inhibitor antigen presenting cells n/a thema EDItEUR::M Medicine and Nursing Cancer Immunology |
| title | Cancer Immunology |
| title_full | Cancer Immunology |
| title_fullStr | Cancer Immunology |
| title_full_unstemmed | Cancer Immunology |
| title_short | Cancer Immunology |
| title_sort | cancer immunology |
| topic | NKG2D CAR T IL-7 prostate cancer cell therapy CD19-CAR-T B cell aplasia KIR PD-1 inhibitory CAR tumor-infiltrating lymphocytes tumor microenvironment immunotherapy NK cells cancer stem cells (CSCs) antibody-dependent cellular cytotoxicity (ADCC) differentiation cytotoxicity IFN-γ osteoclasts MICA/B mAb DNA methylation RNA methylation S-adenosylmethionine (SAM) cancer innate immunity adaptive immunity T cells m6A PD-L1 resistance immune checkpoints cancer vaccine combination immunotherapy TCR diversity organ transplantation carcinoma epidemiologic studies immunosuppression CTLA-4 Treg cells immune checkpoint inhibitors CD28 antigen-presenting cells IL15 colon cancer melanoma uveal BAP1 anti-PD-1 anti-CTLA-4 TIL classical and endemic Kaposi Sarcoma systemic treatment multi-state modelling treatment free interval chemotherapy interferon triple negative breast cancer immunomodulation bispecific antibody sortase A chemo-enzymatic approach anti-CD20 antibody Fab BiFab colorectal cancer dendritic cells Atypical Chemokine Receptor 4 (ACKR4) T-cell priming immune checkpoint blockade primary liver cancer kynurenine pathway immune evasion indoleamine 2,3 dioxygenase 1 tryptophan 2,3 dioxygenase 2 IDO inhibitor antigen presenting cells n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | NKG2D CAR T IL-7 prostate cancer cell therapy CD19-CAR-T B cell aplasia KIR PD-1 inhibitory CAR tumor-infiltrating lymphocytes tumor microenvironment immunotherapy NK cells cancer stem cells (CSCs) antibody-dependent cellular cytotoxicity (ADCC) differentiation cytotoxicity IFN-γ osteoclasts MICA/B mAb DNA methylation RNA methylation S-adenosylmethionine (SAM) cancer innate immunity adaptive immunity T cells m6A PD-L1 resistance immune checkpoints cancer vaccine combination immunotherapy TCR diversity organ transplantation carcinoma epidemiologic studies immunosuppression CTLA-4 Treg cells immune checkpoint inhibitors CD28 antigen-presenting cells IL15 colon cancer melanoma uveal BAP1 anti-PD-1 anti-CTLA-4 TIL classical and endemic Kaposi Sarcoma systemic treatment multi-state modelling treatment free interval chemotherapy interferon triple negative breast cancer immunomodulation bispecific antibody sortase A chemo-enzymatic approach anti-CD20 antibody Fab BiFab colorectal cancer dendritic cells Atypical Chemokine Receptor 4 (ACKR4) T-cell priming immune checkpoint blockade primary liver cancer kynurenine pathway immune evasion indoleamine 2,3 dioxygenase 1 tryptophan 2,3 dioxygenase 2 IDO inhibitor antigen presenting cells n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220111_9783036525730_940 |